HER2 GENE MUTATION
Clinical trials for HER2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new HER2 GENE MUTATION trials appear
Sign up with your email to follow new studies for HER2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177Lu-RAD202 in 30 adults with advanced solid tumors that have a protein called HER2. The drug uses a radioactive particle to seek out and attack cancer cells. The main goals are to check safety, find the right dose, and see how the …
Matched conditions: HER2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 26, 2026 07:32 UTC
-
New combo therapy aims to shrink HER2+ stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding two targeted drugs (pembrolizumab and trastuzumab) to standard chemotherapy can improve outcomes for people with HER2+ cancer of the esophagus or stomach before surgery. About 49 adults with resectable tumors will receive the combination, then surg…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two targeted drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goal is to find the s…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
New drug duo aims to stop rare salivary gland cancer from coming back
Disease control Recruiting nowThis study tests whether adding the targeted drug T-DM1 to standard chemoradiation can prevent HER2-positive salivary gland cancer from returning. About 37 adults with advanced but removable tumors will receive the combination and be followed for two years. The goal is to see if …
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:55 UTC